Actively Recruiting
Evaluation of CMV/EBV-CMI in Haploid HSCT
Led by The First Affiliated Hospital of Soochow University · Updated on 2024-08-15
60
Participants Needed
1
Research Sites
102 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this prospective, open-label, Single Arm, single-center study is to evaluate the cytomegalovirus and Epstein-Barr virus specific immune reestablishment for patients with hemopathy undergoingin prophylaxis for cytomegalovirus in haploid hematopoietic stem cell transplantation(haplo-HSCT) .
CONDITIONS
Official Title
Evaluation of CMV/EBV-CMI in Haploid HSCT
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosed with hemopathy (blood disorder)
- Indicated for haploidentical hematopoietic stem cell transplant
- Receiving prophylaxis for cytomegalovirus
- Signed informed consent agreeing to participate in the study
You will not qualify if you...
- Any condition considered unsuitable for the trial as decided by the investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
First Affiliated Hospital of Soochow University
Suzhou, Jiangsu, China, 215006
Actively Recruiting
Research Team
F
Feng Chen, PhD
CONTACT
D
Depei Wu, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here